Bifogade filer
PDF
Beskrivning
| Land | Norge |
|---|---|
| Lista | 12 |
| Sektor | Hälsovård |
| Industri | Bioteknik |
OSLO, NORWAY - 5 May 2025: Genetic Analysis AS (the "Company", Ticker: GEAN) today announces that its Election Committee has proposed the appointment of Mr. Morten Jurs as the new Chairman of the Board, and Mr. Ove Öhman as a new board member. The proposed change in leadership follows the decision by Dr. Jethro Holter, the current Chairman, to step down from his role and not seek re-election. Dr. Holter will be focusing on his new position as CEO of AdjuTec Pharma.
CEO Ronny Hermansen comments:
"We are excited about the proposal to appoint Morten Jurs as Chairman of the Board. Morten is an experienced leader with a strong track record in diagnostics, pharma, and M&A, and his experience will be invaluable as we continue to scale and expand. His deep understanding of both private and public companies, combined with his extensive board experience, makes him an excellent fit for leading Genetic Analysis through its next phase of growth. We also look forward to welcoming Mr. Ove Öhman to the board. Ove's diverse background and expertise will further enhance our strategic direction as we continue to drive innovation in microbiome diagnostics.
Lastly, I would like to take this opportunity to express my gratitude to Dr. Jethro Holter for his dedication and leadership during his tenure as Chairman. We wish him the very best in his new role as CEO of AdjuTec Pharma."
Proposed new Chairman - Mr. Morten Jurs
Morten Jurs brings a wealth of experience and strategic leadership to the role. Currently serving as CEO of SpinChip Diagnostics, Morten played a key role in the recent acquisition of SpinChip by bioMérieux for NOK 1.6 billion, demonstrating his ability to lead complex business transactions.
With a recognized career spanning both public and private growth companies, Morten's experience includes leadership roles at SpinChip Diagnostics AS, Pronova BioPharma ASA, and Kitron ASA. He has been involved in guiding companies through major changes and has a strong track record in helping businesses grow and succeed.
In addition to his executive experience, Morten brings valuable board experience. Since 2010, he has been a board member and leader of the Audit Committee at Atea ASA, further demonstrating his ability to provide strategic direction and governance for high-growth companies.
Proposed new board member - Mr. Ove Öhman
Ove Öhman is a Swedish serial entrepreneur with a proven track record in the life science and diagnostics industries. Over the past two decades, he has founded or co-founded several companies, including Åmic (1998), Ginolis (2008), Fiomi (2011), Vanadis (2014), Astrego (2016), Moleculent (2021), and Readily Diagnostics (2022). He has served as CEO in several of these ventures and currently holds the position of Chairman of the Board at Readily Diagnostics. He is also a board member of Enaiblers, Moleculent, and Samplefacts.